Clinical research experience

E-Mail Address:[email protected] Date of Birth: Place of Birth:Puerto Rico, USA EDUCATION 1978 B.S., cum laude, Biology and Psychology, Tufts University, Medford, MA M.D., University of Puerto Rico School of Medicine, Rio Piedras, PR Intern in Medicine, Veterans Administration Medical Center and University of Puerto Rico School of Medicine, San Juan, PR Resident in Medicine, Veterans Administration Medical Center and University of Puerto Rico School of Medicine, San Juan, PR Research Fellow in Nephrology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA Clinical Fellow in Nephrology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA HONORS Fellow of the American Society of Nephrology, 2006- APPOINTMENTS Chief, Micropuncture Laboratory, Veterans Administration Medical Center, San Juan, PR Staff Nephrologist, Veterans Administration Medical Center, San Juan, PR Assistant Professor in Medicine, University of Puerto Rico School of Medicine, San Juan, PR Nephrologist, Washington Nephrology Associates, Bethesda, MD Partner, Washington Nephrology Associates, Bethesda, MD Chief, Renal Section, Department of Medicine, Alexandria Hospital, Alexandria, VA Medical Director, Alexandria Kidney Center, Alexandria, VA Volunteer Physician, Arlington Free Clinic, Arlington, VA Managing Partner, Washington Nephrology Associates, Bethesda, MD Chief, Renal Section, Department of Medicine, INOVA Alexandria Hospital, Alexandria, VA LICENSURE Virginia, No. 0101045435 Puerto Rico, No. 8983 CERTIFICATION 1982 National Board of Medical Examiners, No. 271901 American Board of Internal Medicine, No. 102572 American Board of Internal Medicine, Subspecialty Board in Nephrology, No. 102572 MEMBERSHIPS American Society of Nephrology International Society of Nephrology Southern Medical Association Vascular Biology Working Group American College of Physicians Colegio de Médicos-Cirujanos de Puerto Rico HOSPITAL AFFILIATIONS INOVA Alexandria Hospital, Active Woodbridge, VA Virginia Hospital Center, Associate Arlington, VA INOVA Mt. Vernon Hospital, Courtesy Alexandria, VA CLINICAL RESEARCH AFFILIATION Alexandria Kidney Center 4141 Duke St. Alexandria, VA 22304 COMMITEES Inter-American Society of Hypertension, 8th Scientific Meeting, Organizing Committee, 1988-89. Animal Studies Subcommittee, San Juan Veterans Administration Medical Center, 1989-1990. Medical Records Commitee, INOVA Alexandria Hospital, 1993-94. Pharmacy and Therapeutics Committee, INOVA Alexandria Hospital, 1993-present. Medical Executive Committee, INOVA Alexandria Hospital, 1999-2000. Fresenius Medical Care, Medical Director Advisory Committee, 1999-2007. Blood Committee, INOVA Alexandria Hospital, 2002-present. Nutrition Committee, INOVA Alexandria Hospital, 2008-present. PUBLICATIONS 1. Mendez, R.E., Dunn, B.R., Troy, J.L., and Brenner, B.M. Modulation of the natriuretic response to atrial natriuretic peptide by alterations in peritubular Starling forces in the rat. Circ. Res. 59:605-611, 1986. 2. Ballerman, B.J., Dunn, B.R., Mendez, R.E., Zeidel, M.D. Seifter, J.L., and Brenner, B.M. Renal actions of atrial natriuretic peptides. In Atrial Hormones and other Natriuretic Factors. Mulrow, P.J. and Schrier, R., Eds. Clinical Physiology Series. American Physiological Society, Bethesda, pp. 83-92, 1987. 3. Ortola, F.V., Ballerman, B.J., Anderson, S., Mendez, R.E., and Brenner, B.M. Elevated plasma atrial natriuretic peptide in diabetic rats: A potential mediator of hyperfiltration. J. Clin. Invest. 80:670-674, 1987. 4. Mendez, R.E.,Dunn, B.R., Troy, J.L., and Brenner, B.M. Angiotensin II and hyperoncotic albumin modulate the natriuresis induced by atrial natriuretic peptide. In Biologically Active Atrial Peptides. Proceedings of the First World Congress. Brenner, B.M. and Laragh, J.H., Eds. Raven Press, New York, pp 406-409, 1987. 5. Mendez, R.E., Pfeffer, J.M., Ortola, F.V., Bloch, K.D., Anderson, S., Seidman, J.G., and Brenner, B.M. Atrial natriuretic peptide transcription, storage and release in rats with myocardial infarction. Am. J. Physiol. 253 (Heart Circ. Physiol. 22): H1449-H1455, 1987. 6. Mendez, R.E., Dunn, B.R., Troy, J.L., and Brenner, B.M. Atrial natriuretic peptide and furosemide effects on hydraulic pressure in the renal papilla. Kidney Int. 34:36-42, 1988. 7. Mendez, R.E., Pfeffer, J.M., Ortola, F.V., Bloch, K.D., Anderson, S., Seidman, J.G., and Brenner, B.M. Gene expression, storage and release of atrial natriuretic peptide in rats with myocardial infarction. In Biologically Active Atrial Peptides. Proceedings of the Second World Congress. Brenner, B.M. and Laragh, J.H., Eds. Raven Press, New York, pp 428-431, 1988. 8. Mendez, R.E. and Brenner, B.M. Glomerulotubular balance and the regulation of sodium excretion by intrarenal hemodynamics. In The Regulation of Sodium and Chloride Balance. Seldin, D.W. and Giebisch, G., Eds. Raven Press, New York, pp. 105-131, 1990. 9. Mendez, R.E., Lopez, R., Lopez, G., Marti, M.S., and Martinez-Maldonado, M. Effects of dopamine receptor antagonists and renal denervation on amino acid-induced hyperfiltration. Am. J. Physiol. 261 (Renal, Fluid, Electrolyte Physiol. 30): F70-F75, 1991. 10. Méndez, R.E. and Martínez-Maldonado, M. Evaluación clínica de la función renal. In Tratado de Nefrología, 2nd ed., Martínez-Maldonado, M., Rodicio-Díaz, J.L., and Herrera-Acosta, J., Eds. Ediciones Norma S.A., Madrid, pp. 521-536, 1993. Clinical Research Principal Investigator in: 1. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. (Clin. Nephrol. 64:113-123, 2005) 2. FEATURE: A phase-IV, open-label, multi-center trial evaluating the efficacy of Fosrenol compared to existing therapy in adults with end stage renal disease treated for hyperphosphatemia. 3. A Randomized Study of Extended Dosing Regimens for Initiation of Epoetin Alfa Treatment for Anemia of Chronic Kidney Disease. (Clin. J. Am. Soc. Nephrol. 3:1015-1021, 2008) 4. EPIC (Effect of PhosLo on Phosphorus Levels In Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of Calcium Acetate (PhosLo) on Phosphorus Levels in Subjects with Chronic Kidney Disease. 5. A randomized, double-blind, equivalence study of the efficacy of epoetin alfa manufactured by deep tank bioreactor technology and epoetin alfa manufactured by roller-bottle technology for the treatment of anemia in patients with chronic kidney disease receiving hemodialysis. 6. Safety of Ferumoxytol in Patients with Anemia and CKD. (Am. J. Kid. Dis. 52:907-915, 2008) 7. A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy. 8. Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients. (Clin. J. Am. Soc. Nephrol. 4:386-393, 2008) 9. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. (Clin. Nephrol. 72: 252-258, 2009) 10. Prospective, Open-Label, Randomized, Multicenter Study to Demonstrate the Efficacy and Safety of Intravenous RO0503821 for Hemoglobin Control in Patients Transitioning from Chronic Kidney Disease Stage 4 through dialysis. 11. A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis Patients who Self Inject or Receive In-Center Injections. 12. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Withdrawal Study Comparing MCI-196 Versus Placebo Following A 12-Week Dose Titration Period With MCI-196 In Chronic Kidney Disease (Stage V) Subjects on Dialysis (Hemodialysis or Peritoneal Dialysis) with Hyperphosphatemia. 13. ALTITUDE (ALiskiren Trial In Type 2 diabetes Using cardiorenal Disease Endpoints): A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality. 14. Outcome Trial Evaluating the Efficacy and Safety of Norditropin in Adult Patients on Chronic Hemodialysis: A Randomized, Double-blind, Parallel group, Placebo controlled, Multi-centre trial. 15. A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin Alfa. 16. A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects with Chronic Kidney Disease on Hemodialysis with Hyperphosphatemia. 17. A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study using Genz-64470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis. 18. An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of magnesium iron hydroxycarbonate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia. 19. A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects with Moderate and Severe Renal Impairment Including Subjects on Hemodialysis.

Source: http://www.msnva.org/docs/Mendez_Ramon_CV_20112.pdf